Core Insights - Aspire Biopharma Holdings, Inc. has entered into a partnership with Microsize to enhance the development of its lead drug candidate, a sublingual aspirin formulation for emergency treatment of heart attacks [1][2][3] Company Overview - Aspire Biopharma is focused on developing a patent-pending sublingual delivery technology that aims to improve drug effectiveness and reduce side effects by delivering drugs directly into the bloodstream [7] - Microsize has over 30 years of experience in particle size engineering and specializes in micronization and solubility enhancement for pharmaceuticals, operating from FDA-inspected GMP facilities [6] Collaboration Details - The partnership with Microsize will support the clinical trial of Aspire's 162 mg sublingual aspirin, which will compare its efficacy against the current standard of care [2][4] - This collaboration is a strategic move for Aspire, as it secures essential expertise for ongoing product development and regulatory submissions, including a planned New Drug Application by the end of 2026 [3][5] Clinical Trial Information - The upcoming clinical trial will involve 32 healthy volunteers and will evaluate the serum thromboxane B (TxB) inhibition of the sublingual aspirin compared to two chewed 81 mg aspirin tablets [4]